Owkin partners with Boehringer Ingelheim for AI-driven drug discovery
AI company Owkin has signed a licensing agreement with Germany's Boehringer Ingelheim to use its research platform and patient data in the development of drugs targeting cancer and immunology-related diseases. The deal builds on an earlier pilot project from 2025, where Owkin helped prioritize drug targets using tumor samples and biological datasets. This partnership adds Boehringer to a list that includes AstraZeneca (AZN) and Sanofi (SNY), both of which have also partnered with Owkin in recent months. Under the new agreement, Owkin will provide multimodal oncology data and generate additional immunology-related data for Boehringer's research efforts. The collaboration highlights a growing trend among pharmaceutical companies to leverage AI technologies like Owkin’s 'K Pro' platform to accelerate drug discovery processes.
Topics: AI drug discovery Cancer research Immunology Pharmaceutical partnerships